Digital therapeutics (DTx) startup Dopavision has raised funding to develop its lead product, an app designed to slow the progression of myopia – or short-sightedness – in children or adole
A record $14.7 billion in investments was injected into US digital health companies in the first half of this year, overtaking the entire amount raised in 2020 in just six months.
Digital health company Pear Therapeutics has foregone the traditional initial public offering (IPO) route to a stock exchange listing in favour of a merger with a "blank cheque" company.
California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, it
Dermavant is in line to make some big payments to GlaxoSmithKline if its topical psoriasis drug tapinarof reaches the market, and it has just cut a deal to defray those costs.
Digital health player Babylon Health is exploring a merger with a so-called 'blank cheque' company as a route to a public listing, according to a Swedish investment group.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.